Straits Times Index
3,283.94 +3.90 (+0.12%) S&P 500
4,577.11 -85.74 (-1.84%) Dow
35,368.47 -543.34 (-1.51%) Nasdaq
14,506.90 -386.86 (-2.60%) BTC-USD
42,059.31 +147.96 (+0.35%) CMC Crypto 200
998.52 -10.87 (-1.08%)
Vaxart, Inc. (VXRT)
Pre-market:
- Yahoo Finance Video
BioMarin CEO: There are biotech companies 'that probably should not be on the market today’
BioMarin CEO JJ Bienaimé joins Yahoo Finance Live’s Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biotechnology, biotech stocks, and key takeaways from JPMorgan’s annual health care conference.
- Motley Fool
Which Vaccine Stocks Will Make You a Fortune in 2022?
For example, Novavax (NASDAQ: NVAX) soared 2,700% in 2020. Of course, it's impossible to predict with 100% certainty which companies will succeed in the vaccine race -- and whether their share prices will skyrocket. Gritstone Bio (NASDAQ: GRTS) is developing an mRNA vaccine candidate.
- Motley Fool
Is This Vaccine Stock a Buy?
The recent surge in COVID-19 cases caused by the new and more contagious omicron variant of the coronavirus has taught us at least one thing: There's still a dire need for effective vaccines against this potentially deadly disease. Several companies are still looking to enter the coronavirus vaccine market, even though Pfizer and Moderna currently dominate it. One biotech that is slowly advancing a coronavirus vaccine candidate is Vaxart (NASDAQ: VXRT).
